BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2511177)

  • 1. T-cell phenotype is associated with decreased survival in non-Hodgkin's lymphoma.
    Shimizu K; Hamajima N; Ohnishi K; Hara K; Kunii A
    Jpn J Cancer Res; 1989 Aug; 80(8):720-6. PubMed ID: 2511177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the spectrum of postthymic T-cell malignancies in Taiwan. A clinicopathologic study of HTLV-1-positive and HTLV-1-negative cases.
    Su IJ; Wang CH; Cheng AL; Chen YC; Hsieh HC; Chen CJ; Tien HF; Woei-Tsay ; Huang SS; Hu CY
    Cancer; 1988 May; 61(10):2060-70. PubMed ID: 2896068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of immunophenotype in diffuse non-Hodgkin's lymphoma: with special emphasis on the clinical characteristics of T-cell lymphoma].
    Chubachi A; Miura AB; Takatsu H; Yamaguchi A; Nishimura S; Nakayama Y; Akihama T; Miura S; Saitoh M; Watanuki T
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1303-9. PubMed ID: 2069401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].
    Chubachi A; Miura AB; Yamaguchi A; Nishimura S
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Ogawa M; Kimura I; Tominaga S
    J Clin Oncol; 1988 Jan; 6(1):128-41. PubMed ID: 2891797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A clinical and immunological study on non-Hodgkin's malignant lymphoma in nasosinus region].
    Uchizono A; Fukuda K; Itoh K; Ushikai M; Ohyama M
    Nihon Jibiinkoka Gakkai Kaiho; 1990 Apr; 93(4):554-65. PubMed ID: 2376791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictive model for aggressive non-Hodgkin's lymphoma.
    International Non-Hodgkin's Lymphoma Prognostic Factors Project
    N Engl J Med; 1993 Sep; 329(14):987-94. PubMed ID: 8141877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
    Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
    Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP
    J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic factors of invasive non-Hodgkin's lymphoma].
    Yu H; Hong XN; Li J; Peng LP; Ye L
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):461-3. PubMed ID: 17974284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
    Conlan MG; Bast M; Armitage JO; Weisenburger DD
    J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-Hodgkin's lymphoma: correlation of cell surface marker phenotype with clinical features and prognosis].
    Okabe K; Toki H; Kimura Y; Fujii M; Kiura K; Moriwaki S
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):2960-4. PubMed ID: 3490224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
    Bai CM; Yang T; Xü Y; Zhang W; Liu XL; Zhu YL; Chen SC; Shen T
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):142-4. PubMed ID: 16750023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately?
    Cheng AL; Chen YC; Wang CH; Su IJ; Hsieh HC; Chang JY; Hwang WS; Su WC; Liu TW; Tien HF
    J Clin Oncol; 1989 Jun; 7(6):725-31. PubMed ID: 2654330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
    Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
    J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
    Armitage JO; Vose JM; Linder J; Weisenburger D; Harrington D; Casey J; Bierman P; Sorensen S; Hutchins M; Moravec DF
    J Clin Oncol; 1989 Dec; 7(12):1783-90. PubMed ID: 2585020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low grade malignant non-Hodgkin's lymphomas and peripheral pleomorphic T-cell lymphomas in childhood--a BFM study group report.
    Bucsky P; Feller AC; Reiter A; Beck J; Bertram U; Eschenbach C; Gerein V; Lakomek M; Stollmann B; Tausch W
    Klin Padiatr; 1990; 202(4):258-61. PubMed ID: 2203939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.